All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2020-09-28T13:45:49.000Z

Tafasitamab in DLBCL

By Ellen Jenner
Featured
Gilles Salles
Sep 28, 2020
Share:

Bookmark this article

During the 18th International Workshop on Non-Hogkin Lymphoma (iwNHL), the Chair of the Lymphoma Hub, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, spoke about the use of tafasitamab in patients with diffuse large B cell lymphoma (DLBCL).

Tafasitamab in DLBCL

Tafasitamab is a CD19-directed monoclonal antibody approved by the FDA in July 2020 for use in combination with lenalidomide as a second-line treatment for patients with relapsed or refractory (R/R) DLBCL. Approval was based on results from the phase II L-MIND study. In this interview, Gilles Salles discusses these results and questions how we might sequence the L-MIND regimen compared to chimeric antigen receptor (CAR) T cell therapy given that the epitope recognised by tafasitamab overlaps with the epitope targeted by CD19-directed CAR T cells.

More about...
Aggressive B-cell lymphomasDiffuse large B-cell lymphomaTafasitamab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
71 votes - 14 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox